Movement Alert｜LEADS BIOLABS-B Rises 5.06% in Regular Trading, Multiple Pipeline Catalysts Drive Positive Sentiment

Market Focus

Aug 14

On August 14, LEADS BIOLABS-B rose 5.06% in regular trading, trading at HK$72.3/share, with turnover of HK$119 million.

The movement was driven by a cluster of recent positive developments. On August 6, the company announced that its core product Welixin (Opamtistomig, a PD-L1/4-1BB bispecific antibody) Phase II clinical study for first-line hepatocellular carcinoma treatment successfully entered the expansion stage following safety lead-in evaluation. Additionally, the IND application for Welixin in metastatic colorectal cancer was approved by CDE on August 3, and the Phase II biliary tract cancer study completed enrollment of all 70 patients on July 30.

Further catalysts include Zhejiang Securities initiating coverage with a Buy rating, projecting revenue of RMB 284-756 million for 2026-2028. The BLA for Welixin was previously accepted into priority review, and six research results were selected for the ESMO annual meeting, reinforcing pipeline value realization and commercial visibility.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1145060311"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1145060311\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1145060311?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-14 14:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145060311","market":"hk","top_or_hot":-1,"title":"Movement Alert｜LEADS BIOLABS-B Rises 5.06% in Regular Trading, Multiple Pipeline Catalysts Drive Positive Sentiment","media":"Market Focus","content":"<p><p>On August 14, LEADS BIOLABS-B rose 5.06% in regular trading, trading at HK$72.3/share, with turnover of HK$119 million.</p><p>The movement was driven by a cluster of recent positive developments. On August 6, the company announced that its core product Welixin (Opamtistomig, a PD-L1/4-1BB bispecific antibody) Phase II clinical study for first-line hepatocellular carcinoma treatment successfully entered the expansion stage following safety lead-in evaluation. Additionally, the IND application for Welixin in metastatic colorectal cancer was approved by CDE on August 3, and the Phase II biliary tract cancer study completed enrollment of all 70 patients on July 30.</p><p>Further catalysts include Zhejiang Securities initiating coverage with a Buy rating, projecting revenue of RMB 284-756 million for 2026-2028. The BLA for Welixin was previously accepted into priority review, and six research results were selected for the ESMO annual meeting, reinforcing pipeline value realization and commercial visibility.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜LEADS BIOLABS-B Rises 5.06% in Regular Trading, Multiple Pipeline Catalysts Drive Positive Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜LEADS BIOLABS-B Rises 5.06% in Regular Trading, Multiple Pipeline Catalysts Drive Positive Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-14 14:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 14, LEADS BIOLABS-B rose 5.06% in regular trading, trading at HK$72.3/share, with turnover of HK$119 million.</p><p>The movement was driven by a cluster of recent positive developments. On August 6, the company announced that its core product Welixin (Opamtistomig, a PD-L1/4-1BB bispecific antibody) Phase II clinical study for first-line hepatocellular carcinoma treatment successfully entered the expansion stage following safety lead-in evaluation. Additionally, the IND application for Welixin in metastatic colorectal cancer was approved by CDE on August 3, and the Phase II biliary tract cancer study completed enrollment of all 70 patients on July 30.</p><p>Further catalysts include Zhejiang Securities initiating coverage with a Buy rating, projecting revenue of RMB 284-756 million for 2026-2028. The BLA for Welixin was previously accepted into priority review, and six research results were selected for the ESMO annual meeting, reinforcing pipeline value realization and commercial visibility.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"","article_id":"1145060311","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145060311","pubTimestamp":1786688645,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 14, LEADS BIOLABS-B rose 5.06% in regular trading, trading at HK$72.3/share, with turnover of HK$119 million.The movement was driven by a cluster of recent positive developments. On August...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09887":"维立志博-B"},"translate_title":"走势警报|LEADS BIOLABS-B 常规交易上涨 5.06%，多个管道催化剂推动积极情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"On August 14, LEADS BIOLABS-B rose 5.06% in regular trading, trading at HK$72.3/share, with turnover of HK$119 million.The movement was driven by a cluster of recent positive developments. On August 6, the company announced that its core product Welixin (Opamtistomig, a PD-L1/4-1BB bispecific antibody) Phase II clinical study for first-line hepatocellular carcinoma treatment successfully entered the expansion stage following safety lead-in evaluation. Additionally, the IND application for Welixin in metastatic colorectal cancer was approved by CDE on August 3, and the Phase II biliary tract cancer study completed enrollment of all 70 patients on July 30.Further catalysts include Zhejiang Securities initiating coverage with a Buy rating, projecting revenue of RMB 284-756 million for 2026-2028. The BLA for Welixin was previously accepted into priority review, and six research results were selected for the ESMO annual meeting, reinforcing pipeline value realization and commercial visibility.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}